Clinical Trial Search

Primary: Number of Participants With Adverse Events Including Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) — 0; 0; 0; 0 Participants

Primary: Renal Function — 65.70 mL/min/1.73 m2

Primary: Total Amount of Opioid Used — 15; 0 milligrams

Primary: Change in Plasma Functional Alpha-1 Antitrypsin (AAT) Levels — -0.1; 2.3; 2.3; 2.1 micromole per liter — p=<0.0001

Primary: the Incidence of Post-ESWL Pancreatitis — 60; 84 Participants

Primary: Changes in the Oxford Ankle Foot Questionnaire for Children (OxAFQ-C) Scores — 0.27; 0.22; 0.19; 0.18 score on a scale

Primary: Serum Sodium Concentration — 138.7 mmol/L

Primary: Concentration of Doravirine in Seminal Plasma Fluid — 127 ng/ml

Primary: Esthetic Changes — 1.90; 5.50; 5.53; 5.35 score on a scale

Primary: Progression Free Survival — 16.7 Months

Primary: Maximum Tolerated Dose of Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) in Participants With Advanced…

Primary: TOTAL POLYP SCORE (TPS) — 4.67; 5.24 units on a scale — p=<0.05

Primary: Death Within 8 Weeks of the Study Cell Infusion Thought to be Definitely or Probably Related to Chimeric Antigen Receptor (CAR) T Cell Therapy — 0; 0; 1; 0 Participants

Primary: Number of Participants Not Requiring Removal or Reoperation of the Implant — 69 Participants

Primary: Number of Adverse Events — 236; 14 adverse events